MAN1A1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human Raji B lymphoblastoid cell line, featuring targeted disruption of the MAN1A1 gene. This pool of edited cells provides a loss-of-function model for investigating the early steps of N-glycan trimming and their impact on glycoprotein maturation. As a polyclonal knockout, the product offers a heterogeneous population with MAN1A1 gene disruption, enabling studies on the collective effects of impaired alpha-1,2-mannosidase activity without selection for a single clonal genotype.
The Raji cell line is an Epstein-Barr virus (EBV)-positive B lymphocyte model derived from a Burkitt lymphoma patient. It is widely employed in immunological research to examine B cell receptor (BCR) signaling, complement receptor function, and apoptotic mechanisms. The EBV-transformed background renders Raji cells particularly valuable for studying oncogenic signaling and lymphomagenesis, making them a relevant host for probing glycosylation-dependent processes in B cell malignancies.
The MAN1A1 gene encodes an ER-resident alpha-1,2-mannosidase that removes a terminal alpha-1,2-linked mannose from the middle branch of Man9GlcNAc2, producing Man8GlcNAc2 isomer B. This trimming step directs glycoprotein fate: properly folded proteins proceed to the Golgi for complex N-glycan synthesis by MGAT1 and MGAT2, while misfolded forms interact with calnexin and calreticulin and are targeted for ER-associated degradation (ERAD) by EDEM family proteins. MAN1A1 is regulated by the unfolded protein response (UPR) via transcription factors ATF6 and XBP1, and its activity is sensitive to ER stress inducers like tunicamycin. The enzyme cooperates with other mannosidases (MAN1B1, MAN1C1), glucosidases (GCS1, GANAB), and the cargo receptor ERGIC-53 to maintain glycoprotein homeostasis.
In Raji B cells, MAN1A1 knockout eliminates this mannose-trimming step, altering the glycosylation of surface receptors such as BCR and integrins. This disruption likely modulates B cell signaling, apoptosis, and lymphoma biology, providing a model to study how glycoprotein quality control defects influence immune receptor function and cancer cell survival. The polyclonal population enables assessment of collective ER stress responses and the consequences of aberrant N-glycan processing in a lymphoblastoid background.
Researchers can employ these cells in diverse assays: lectin blotting with ConA or GNL to detect high-mannose and hybrid glycan shifts, flow cytometry for BCR and integrin surface expression, and RT-qPCR for UPR genes (XBP1, ATF6) under basal or ER stress conditions. Apoptosis assays using Annexin V, mass spectrometry-based glycan profiling, and Endo H/N-glycosidase F digestion further resolve structural N-glycan changes. The model supports investigations into glycosylation-targeted drugs, congenital disorders of glycosylation, and glycoproteomic studies in B lymphoma. For further information, contact Ascent Research.
